In addition, Imatinib mesylate (STI571), an inhibitor of alpha- and beta-platelet-derived growth factor receptors (PDGFR) has recently been tested in clinical trials against pancreatic cancer [52]. Here, PDGFRB is linked to familial pancreatic carcinoma.